Tiziana Life Sciences is trading 5.25% down at $0.96, with no new company-specific announcement dated August 12, 2026 found to explain the decline.

  • Latest official updates were August 4 and August 6 insider-share purchases by CEO Ivor Elrifi.
  • Those purchases predate the move and do not establish causation.
  • Broader markets are higher, so the decline is not aligned with today’s macro direction.